Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study
Open Access
- 1 April 2025
- journal article
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 31 (2) , 394-408
Abstract
Background/Aims: The World Health Organization set the goal of eliminating hepatitis C virus (HCV) by 2030, with 80% and 65% reductions in HCV incidence and mortality rates, respectively. We aimed to evaluate the health benefits, cost-effectiveness and return on investment (ROI) of HCV elimination.Methods: Using an HCV transmission compartmental model, we evaluated the benefits and costs of different strategies combining screening and treatment for Chinese populations. We identified strategies to achieve HCV elimination and calculated the incremental cost-effectiveness ratios (ICERs) per disability-adjusted life year (DALY) averted for 2022–2030 to identify the optimal elimination strategy. Furthermore, we estimated the ROI by 2050 by comparing the required investment with the economic productivity gains from reduced HCV incidence and deaths.Results: The strategy that results in the most significant health benefits involves conducting annual primary screening at a rate of 14%, re-screening people who inject drugs annually and the general population every five years, and treating 95% of those diagnosed (P14-R4-T95), preventing approximately 5.75 and 0.44 million HCV infections and deaths, respectively, during 2022–2030. At a willingness-to-pay threshold of $12,615, the P14-R4-T95 strategy is the most cost-effective, with an ICER of $5,449/DALY. By 2050, this strategy would have a net benefit of $120,997 million (ROI=0.868).Conclusions: Achieving HCV elimination in China by 2030 will require significant investment in large-scale universal screening and treatment, but it will yield substantial health and economic benefits and is cost-effective.Keywords
Funding Information
- National Natural Science Foundation of China (71874209)
- Health Commission of Hunan Province (202113050283)
- Central Universities of Central South University (2023ZZTS0924)
- Hunan Provincial Natural Science Foundation of China (2023JJ60503)
- High Performance Computing Center of Central South University
- UK National Institute for Health and Care Research (NIHR) Health Protection Research Unit (HPRU) in Behavioural Science and Evaluation at the University of Bristol (NIHR200877)
- Wellcome Trust (WT 220866/Z/20/Z)
- UK NIHR (NIHR133208)
This publication has 43 references indexed in Scilit:
- Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling studyThe Lancet Gastroenterology & Hepatology, 2017
- Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World DataPLOS ONE, 2016
- Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness modelGut, 2016
- Disability weights for the Global Burden of Disease 2013 studyThe Lancet Global Health, 2015
- Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH‐C) patients: an economic model from five European countriesJournal of Viral Hepatitis, 2015
- Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalenceGlobal Public Health, 2014
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task ForceValue in Health, 2013
- [A sero-epidemiological study on hepatitis C in China].2011
- Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviewsThe Lancet, 2011
- The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activitiesJournal of Medical Economics, 2011